NexaVant

N/A

Report date: 2025/03/20 15:06:09
NME

Base Information

Drug NameNexaVant
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 3 agonists
TargetsToll like receptor 3
Therapy Area/IndicationsHead and Neck NeoplasmsTriple Negative Breast NeoplasmsMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNa Vaccine Institute
China Registration ClassN/A

Develop Information

Active CompaniesNa Vaccine Institute
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsTriple Negative Breast NeoplasmsMelanoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A